Changes of clotting and fibrinolytic factors levels during Danazol therapy for application of treatment of hereditary hemorrhagic disease.

Danazol, a derivative of 17α-ethinyl testosterone which is a synthetic steroid with antigonadotropic properties has been used in the treatment of endometriosis. The efficacy of Danazol due to long-term administration resulted in a reduction of menstrual blood loss. The purpose of this investigation was to study not only the influence of Danazol on clotting and fibrinolytic activities for patients with endometriosis, but also to know that Danazol therapy may decrease menstrual blood loss in patients with hereditary hemorrhagic disease as reported by Soma et al.Results: 1) There were steady rises in F VIII and F IX after 4 months administration of Danazol, while no rises of such factors were observed in women given androgen. 2) No significant increase of platelets and other clotting factors was observed during Danazol treatment, even though a transient decrease of fibrinogen was seen. 3) No significant changes of fibrinolytic activities such as α1-AT, α2-MG, AT-III and C1-INA were observed. 4) Plasma levels of kallikrein inhibitor at the onset of menstruation in women treated with Danazol was higher than the control group. 5) However, in vitro changes of clotting as well as fibrinolytic activities depending upon concentrations of Danazol were not evident.In conclusion, Danazol therapy on coagulation and fibrinolytic factors was different from the effect of Pill treatment. Therefore, it will be applicable to clinical use of the treatment of hemorrhagic disorders.